GRN-300 is under clinical development by Greenfire Bio and currently in Phase I for Ovarian Cancer. According to GlobalData, Phase I drugs for Ovarian Cancer have a 74% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how GRN-300’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

GRN-300 overview

GRN-300 is under development for the treatment of recurrent ovarian cancer, endometrial cancer, primary peritoneal cancer, fallopian tube cancer, triple-negative breast cancer, prostate cancer, acute myeloid leukemia (AML), diffuse large B-cell lymphoma and lung cancer. It is administered through oral route. It acts by targeting serine/threonine-protein kinase (SIK2) and serine/threonine-protein kinase (SIK3). The drug candidate is developed based on fragment-field drug design (FFDD) technology platform.

Greenfire Bio overview

Greenfire Bio (Greenfire) is a life science company that builds a diversified product pipeline by developing early-stage assets. The company acquires, licenses, partners and invests in differentiated pre-clinical oearly clinical stage medical products to bridge the translational medicine gap and accelerate development. Its lead product candidate GRN-300, an orally bioavailable small molecule dual inhibitor of salt inducible kinases 2 and 3 (SIK2, SIK3) for the treatment ovarian cancer. Greenfire is also evaluating drugs targeting triple-negative breast cancer (TNBC), prostate, diffuse large B-cell lymphoma (DLBCL), melanoma and AML cancers. Greenfire is headquartered in Austin, Texas, the US.

For a complete picture of GRN-300’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.